Mobile App for BP Control (SMART-BP)
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Mobile Application
Standard SMBP
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Male and female patients with essential hypertension aged 19 years and above.
- Patients with essential hypertension who are taking one or more antihypertensive drugs.
- Patients whose average systolic and diastolic BP measured 3 times on the reference arm in the sitting position during Visit 1 is greater than 140 mmHg and 90 mmHg, respectively.
- Patients voluntarily consent to participate in this clinical trial
- Patients who can use a smartphone
Exclusion Criteria:
- Patients with a history of secondary hypertension or suspected secondary hypertension, including coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, and polycystic kidney disease.
- Patients with a mean systolic BP ≥ 200 mmHg or diastolic BP ≥ 110 mmHg at the screening visit.
- Patients with ≥ 20 mmHg difference between the highest and the lowest sitting systolic BP or ≥ 10 mmHg difference between highest and lowest diastolic BP, which is confirmed by triplicate measurements from the reference arm at screening.
- Patients with uncontrolled diabetes (HbA1c ≥ 9.0%).
- Patients who have been continuously taking other medications such as systemic steroids, thyroid hormones, oral contraceptives (except for menopausal hormone replacement therapy), psychiatric drugs, non-steroidal anti-inflammatory drugs, sympathetic drugs, and immune suppressants, which have the potential to affect BP.
- Patients with symptomatic orthostatic hypotension.
- Patients with a history of malignant tumors, including leukemia and lymphoma, within the past 5 years.
- Patients with a history of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.
Patients with clinically significant kidney and liver diseases, such as those on dialysis, liver cirrhosis, biliary obstruction, and hepatic failure, or those who show the following findings during the screening visit:
- Alanine transaminase or aspartate transaminase level is at least 3 times higher than the normal upper limit;
- Total bilirubin level is more than twice the normal upper limit;
- Blood urea nitrogen level is more than twice the normal upper limit;
- Alkaline phosphatase level is more than twice the normal upper limit;
- Creatinine clearance level is less than 10 mL/min.
Patients with a history of the following diseases in the past 6 months, which are determined to be clinically significant by the investigator:
- Heart failure (NYHA class III and IV), ischemic heart diseases (coronary artery diseases, such as angina pectoris and myocardial infarction), peripheral vascular diseases, hemodynamically significant valve stenosis, and arrhythmia.
- Severe cerebrovascular events, including stroke, cerebral infarction, and cerebral hemorrhage.
- Patients with shock.
- Patients with a history of alcohol or drug abuse.
- Patients with potential pregnancy or breastfeeding.
- Patients who will be judged as both legally and psychologically inadequate to participate in the clinical study by the investigator.
- Patients who have participated in clinical studies with other investigational drug products within 4 weeks prior to screening.
Sites / Locations
- Korea Univ. Guro Hospital
- Hallym University Sacred Heart Hospital
- Seoul National University Bundang Hospital
- Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
- Kyung Hee University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
SMBP_only
SMBP_mobile_app
Arm Description
Standard treatment with SMBP
SMBP with mobile App based feed-back algorithm
Outcomes
Primary Outcome Measures
mean home systolic BP change
mean home systolic BP change from baseline to 24 weeks (Visit 2)
Drug adherence
Drug adherence using pill count
Secondary Outcome Measures
Diastolic BP change
mean home diastolic BP change from baseline
office BP change
office systolic or diastolic BP change from baseline
Full Information
NCT ID
NCT04470284
First Posted
July 6, 2020
Last Updated
May 2, 2023
Sponsor
Seoul National University Bundang Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04470284
Brief Title
Mobile App for BP Control
Acronym
SMART-BP
Official Title
Self-Monitoring of and Feed-back Using APP. in TReatment of UnconTroled Blood Pressure (SMART-BP)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
September 1, 2019 (Actual)
Primary Completion Date
March 15, 2021 (Actual)
Study Completion Date
March 15, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Bundang Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
SMART-BP is a randomized, controlled study in which hypertensive patients are allocated to self monitoring of blood pressure monitoring (SMBP) only group or SMBP with mobile App based feed-back algorithm (SMBP-App) group. The App based feed-back algorithm will provide the patients with instruction in response to the measured BP value, e.g. remind of taking drug, if high blood pressure is detected.
The primary outcomes are mean systolic BP change and drug compliance at 24-weeks. Secondary endpoints include mean diastolic BP change at 12-week, mean systolic and diastolic BP change at 12 and 24 weeks, and drug compliance.
Detailed Description
This trial is a prospective, randomized, open-label, multicenter trial to evaluate the efficacy of SMBP with mobile health application (SMBP-App) compared with SMBP alone.
Patients with hypertension will be randomly assigned to SMBP-App (intervention) and SMBP along (control) groups. In SMBP group the patients perform home blood pressure measurement and usual care. In SMBP-App group the patients perform home blood pressure and receive extra alarm and instructions from the mobile application in response to the obtained blood pressure value.
The aim of this study is to evaluate whether SMBP-App is superior to SMBP alone in terms of blood pressure reduction and improved drug compliance in patients with hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
186 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SMBP_only
Arm Type
Active Comparator
Arm Description
Standard treatment with SMBP
Arm Title
SMBP_mobile_app
Arm Type
Experimental
Arm Description
SMBP with mobile App based feed-back algorithm
Intervention Type
Other
Intervention Name(s)
Mobile Application
Intervention Description
SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.
Intervention Type
Other
Intervention Name(s)
Standard SMBP
Intervention Description
Standard treatment (SMBP-alone)
Primary Outcome Measure Information:
Title
mean home systolic BP change
Description
mean home systolic BP change from baseline to 24 weeks (Visit 2)
Time Frame
24 weeks
Title
Drug adherence
Description
Drug adherence using pill count
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Diastolic BP change
Description
mean home diastolic BP change from baseline
Time Frame
12 weeks and 24 week
Title
office BP change
Description
office systolic or diastolic BP change from baseline
Time Frame
12 weeks and 24 week
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients with essential hypertension aged 19 years and above.
Patients with essential hypertension who are taking one or more antihypertensive drugs.
Patients whose average systolic and diastolic BP measured 3 times on the reference arm in the sitting position during Visit 1 is greater than 140 mmHg and 90 mmHg, respectively.
Patients voluntarily consent to participate in this clinical trial
Patients who can use a smartphone
Exclusion Criteria:
Patients with a history of secondary hypertension or suspected secondary hypertension, including coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, and polycystic kidney disease.
Patients with a mean systolic BP ≥ 200 mmHg or diastolic BP ≥ 110 mmHg at the screening visit.
Patients with ≥ 20 mmHg difference between the highest and the lowest sitting systolic BP or ≥ 10 mmHg difference between highest and lowest diastolic BP, which is confirmed by triplicate measurements from the reference arm at screening.
Patients with uncontrolled diabetes (HbA1c ≥ 9.0%).
Patients who have been continuously taking other medications such as systemic steroids, thyroid hormones, oral contraceptives (except for menopausal hormone replacement therapy), psychiatric drugs, non-steroidal anti-inflammatory drugs, sympathetic drugs, and immune suppressants, which have the potential to affect BP.
Patients with symptomatic orthostatic hypotension.
Patients with a history of malignant tumors, including leukemia and lymphoma, within the past 5 years.
Patients with a history of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.
Patients with clinically significant kidney and liver diseases, such as those on dialysis, liver cirrhosis, biliary obstruction, and hepatic failure, or those who show the following findings during the screening visit:
Alanine transaminase or aspartate transaminase level is at least 3 times higher than the normal upper limit;
Total bilirubin level is more than twice the normal upper limit;
Blood urea nitrogen level is more than twice the normal upper limit;
Alkaline phosphatase level is more than twice the normal upper limit;
Creatinine clearance level is less than 10 mL/min.
Patients with a history of the following diseases in the past 6 months, which are determined to be clinically significant by the investigator:
Heart failure (NYHA class III and IV), ischemic heart diseases (coronary artery diseases, such as angina pectoris and myocardial infarction), peripheral vascular diseases, hemodynamically significant valve stenosis, and arrhythmia.
Severe cerebrovascular events, including stroke, cerebral infarction, and cerebral hemorrhage.
Patients with shock.
Patients with a history of alcohol or drug abuse.
Patients with potential pregnancy or breastfeeding.
Patients who will be judged as both legally and psychologically inadequate to participate in the clinical study by the investigator.
Patients who have participated in clinical studies with other investigational drug products within 4 weeks prior to screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dong-Ju Choi, MD, PhD
Organizational Affiliation
Seoul National Univeristy Bundang Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Korea Univ. Guro Hospital
City
Seoul
State/Province
Guro
ZIP/Postal Code
08308
Country
Korea, Republic of
Facility Name
Hallym University Sacred Heart Hospital
City
Anyang
Country
Korea, Republic of
Facility Name
Seoul National University Bundang Hospital
City
Seongnam
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
City
Seoul
Country
Korea, Republic of
Facility Name
Kyung Hee University Hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
36217600
Citation
Choi DJ, Park JJ, Yoon M, Park SJ, Jo SH, Kim EJ, Kim SJ, Lee S. Self-Monitoring of Blood Pressure and Feed-back Using APP in TReatment of UnconTrolled Hypertension (SMART-BP): A Randomized Clinical Trial. Korean Circ J. 2022 Oct;52(10):785-794. doi: 10.4070/kcj.2022.0133.
Results Reference
derived
Learn more about this trial
Mobile App for BP Control
We'll reach out to this number within 24 hrs